Available Until 2/19/2027

Navigating the Complex Landscape of Pulmonary Arterial Hypertension: A Roadmap for Pharmacists

ACPE Number: 0204-0000-25-409-H01-P
Content Release Date: February 19, 2026
Expiration Date: February 19, 2027
Activity Type: Application-based
CE Credits: 1.5 contact hours (0.15 CEUs)
Activity Fee:  Free

Activity Overview

The last 30 years have seen significant advances in the diagnosis, treatment, and management of pulmonary arterial hypertension (PAH). Improvements in understanding the pathways underlying endothelial dysfunction and vascular arteriole remodeling involved in the pathogenesis of PAH, targeted therapies, and enhanced diagnostic and monitoring tools are reflected in new evidence-based guidelines. This educational activity will present the latest guidelines and recommended treatment options for PAH, including drug selection, combination therapies, and when and how to adjust and escalate treatment. This activity will also discuss drug therapy mechanisms of action, potential interactions, adverse effects, and considerations to support access and adherence.

*Please note, this activity was presented live on December 9, 2025 as part of the ASHP 2025 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study.

Provided by ASHP

Supported by an educational grant from Merck